It can be difficult to evaluate a service while also preparing for a medical conversation. A short list helps separate the questions that a clinician should answer from those that belong with billing support.
This guide does not screen you for treatment or tell you what to take. It is a way to make sure the conversation addresses the points you need clarified.
Ask the clinician about the proposed treatment
Ask what exact product is being considered, why it is appropriate to discuss, and what monitoring or follow-up would be needed. Bring your own medical questions to the licensed professional rather than asking an editorial site to resolve them.
If compounding is part of the proposal, ask the clinician to explain that choice and the relevant alternatives. The FDA’s discussion provides background on why product identity deserves attention.
Ask the service about the transaction
Request a written explanation of the selected plan, included services, additional charges and renewal timing. A membership and a medication purchase may be separate; Mochi’s public presentation explicitly makes that distinction.
Do not assume the lowest visible medication figure is the entire cost of care. Mark unconfirmed expenses as questions to resolve rather than filling them in from an unrelated advertisement.
Source: Mochi Health official website
Ask how follow-up works
Identify who handles a concern after the visit and how to reach the dispensing pharmacy. Keep the actual organization names, not just the platform’s general support link.
Once the pharmacy is assigned, use official licensing resources to check its identity. A source-based provider review can help you prepare but cannot verify a future prescription on your behalf.
Our assessment
A useful consultation outline leaves room for an answer you did not anticipate. Keep the proposed treatment, follow-up and purchase terms aligned before relying on a provider comparison.
Source record & limits
Official sources checked October 16, 2026. Commercial pages support descriptions of offers, not independent proof of outcomes. We did not enroll, place an order, verify an individual prescription, or measure support performance.
- FDA: concerns with unapproved GLP-1 drugs — Federal regulator explanation of compounding limits and risks
- Mochi Health official website — Provider treatment menu, membership presentation and exclusions
- FDA: locate a state-licensed online pharmacy — Links to state pharmacy licensing resources
Medical decisions belong with a licensed clinician. Compounded drugs are not FDA-approved; the FDA explains the limits and risks.